DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.

Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks

3.0 mg/kg, intravenous infusion, D1, every 2 weeks